Rick Pazdur on FDA's Challenges and Opportunities Amidst China's Rising Competition
Rick Pazdur addresses the significant shifts at the FDA, highlighting how competition from China may necessitate a restructuring of the agency.
Editorial Staff
1 min read
Updated 10 days ago
Rick Pazdur has pointed out that the FDA is undergoing considerable changes, which could be linked to the increasing competition from China.
He suggests that while these challenges are significant, they also present opportunities for the agency to adapt and improve.
Pazdur emphasizes the need for the FDA to consider restructuring in response to these evolving realities.